Molecular biomarkers play an increasing role for the diagnosis and prediction of progression or therapy response in complex diseases such as cancer. Individualized treatment decisions and specialized drugs warrant the need to broaden the focus from singular biomarkers to pathways. While Omics technologies allow the parallel measurement of many different markers, pathway databases offer vast amounts of knowledge on biological networks. Our aim is to present the most relevant, meaningful and interpretable patient-specific pathways to clinicians and researchers. Thus, we aim to reduce the gap between patient centered routine documentation and ontology-driven pathway and gene annotation and establish a seamless data-flow from single patient data to Systems Medicine.